In this episode of BioTalk, Rich Bendis, President and CEO of BioHealth Innovation, Inc., sits down with Peter Ronco, Chief Executive Officer of Emmes, a global full-service Clinical Research Organization (CRO). Peter discusses his transition from leading roles at Janssen R&D and Bristol Myers Squibb to guiding Emmes' strategic direction and operations.
Peter introduces Emmes, its growth as a full-service CRO, and the recent partnership with New Mountain Capital that has accelerated global acquisitions and diversified services. He also discusses the formation of the Emmes Group, which includes Veridix AI, and the latest partnership with Mimansa AI, highlighting the impact of AI in clinical research.
Listen now via your favorite podcasting platforms:
Apple:https://apple.co/2QwoEIl
Spotify: https://spoti.fi/4dJCNf6
Amazon Music: https://amzn.to/3Zfhzl7
TuneIn: https://bit.ly/3Xbi3Gf
The conversation also covers the strategic importance of Rockville, Maryland, as Emmes' headquarters and why Montgomery County is an ideal location. Peter wraps up by outlining Emmes' future growth plans.
About Peter Ronco: Peter Ronco is the CEO of Emmes, with extensive global experience in pharmaceutical development. He oversees the strategic and operational aspects of Emmes, a leading CRO operating in over 30 countries. Prior to Emmes, Peter held senior roles at Janssen R&D and Bristol Myers Squibb.
Tune in to BioTalk for a focused discussion with Peter Ronco on Emmes' growth, AI in clinical research, and the future of global drug development.
Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com).
Peter is an accomplished drug developer and innovative senior pharmaceutical executive who is currently the CEO of Emmes as well as advising boards, private equity investors, and leaders across the pharmaceutical and biotech industry. He has extensive global experience across a broad range of therapeutic areas, including oncology, immunology, neuroscience, vaccines, anti-infectives, cardiovascular and retinal gene therapy - from First in Human to Medical Affairs.
In his current role as CEO of Emmes, he is responsible for setting both the strategic direction and the day-to-day operations of the full service CRO operating in 30+ countries and across multiple disease areas including ophthalmology, vaccines, rare disease, cell & gene therapy, and neuroscience. Emmes is collaborating with more than 210 sponsors, within the pharmaceutical/biotech industry, government, including over a dozen institutes of the National Institutes of Health (NIH), academic organizations, and non‐profit foundations.
Until January 2023, Peter was the Head of Global Development at Janssen R&D where he was responsible for leading the Global Development organization (including statistics, clinical pharmacology, clinical operations, data operations, project and portfolio management, etc.) in support of delivering a broad ranging portfolio of 450+ studies across all therapeutic areas and all phases from PhI -IV. In this role he managed a 10,000+ globally distributed organization and a $2bn+ operating budget to support the design of innovative drug development programs and the implementation of innovative approaches to trial design and execution including trial virtualization, digital health, patient-centered research, and diversity in clinical trials.
Prior to joining Janssen in 2017, Peter was the Senior Vice President of Global Clinical Operations at Bristol Myers-Squibb where he had spent 14 years holding positions of increasing leadership scope in Medical Affairs, Regulatory Operations and R&D Operations. He also served on the TransCelerate Biopharmaceutical Board of Directors. Prior to joining BMS, Peter was a consultant with Accenture, focusing on post-merger integration of R&D organizations. He is a graduate of Nottingham University in the UK and lives in Chester, NJ.